113 related articles for article (PubMed ID: 20722101)
21. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach.
Giridhara Prema S; Chandrasekaran J; Kanekar S; George M; Prasad TSK; Raju R; Dagamajalu S; Balaya RDA
OMICS; 2024 Jan; 28(1):8-23. PubMed ID: 38190280
[TBL] [Abstract][Full Text] [Related]
23. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
24. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
25. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
26. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
27. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
[TBL] [Abstract][Full Text] [Related]
28. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
29. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells.
Krkoška M; Paruch K; Šošolíková T; Vázquez-Gómez G; Herůdková J; Novotný J; Ovesná P; Sova P; Hyršlová Vaculová A
Biol Chem; 2024 Jun; 405(6):395-406. PubMed ID: 38452398
[TBL] [Abstract][Full Text] [Related]
31. RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.
Mao D; Che J; Han S; Zhao H; Zhu Y; Zhu H
Mol Med Rep; 2015 Nov; 12(5):6635-41. PubMed ID: 26299671
[TBL] [Abstract][Full Text] [Related]
32. [Silencing of cell cycle checkpoint kinase gene enhances cisplatin-induced apoptosis of lung cancer cells].
Ye F; Xie DX; Lu YP; Gao QL
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):804-9. PubMed ID: 20137342
[TBL] [Abstract][Full Text] [Related]
33. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.
Materna V; Stege A; Surowiak P; Priebsch A; Lage H
Biochem Biophys Res Commun; 2006 Sep; 348(1):153-7. PubMed ID: 16876126
[TBL] [Abstract][Full Text] [Related]
34. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
35. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
36. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
37. CHK1 cleavage in programmed cell death is intricately regulated by both caspase and non-caspase family proteases.
Okita N; Yoshimura M; Watanabe K; Minato S; Kudo Y; Higami Y; Tanuma S
Biochim Biophys Acta; 2013 Jan; 1830(1):2204-13. PubMed ID: 23085068
[TBL] [Abstract][Full Text] [Related]
38. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo.
Feng Z; Xu S; Liu M; Zeng YX; Kang T
Cancer Lett; 2010 Nov; 297(2):190-7. PubMed ID: 20619533
[TBL] [Abstract][Full Text] [Related]
39. DHA but not AA Enhances Cisplatin Cytotoxicity in Ovarian Cancer Cells.
Zajdel A; Kałucka M; Chodurek E; Wilczok A
Nutr Cancer; 2018 Oct; 70(7):1118-1125. PubMed ID: 30204485
[TBL] [Abstract][Full Text] [Related]
40. Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.
He C; Liu D; Lin W
Biomaterials; 2015 Jan; 36():124-33. PubMed ID: 25315138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]